Drug Search Results

GSK-2981278

Alternative Names: gsk-2981278, gsk2981278, gsk 2981278
Latest Update: 2023-09-15
Latest Update Note: News Article

Product Description

GSK2981278 is an inverse agonist of retinoic acid receptor-related orphan receptor (ROR) gamma.

Mechanisms of Action: RORG Agonist

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Topical

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: GlaxoSmithKline
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for GSK-2981278

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Psoriasis

Trial	Phase	Trial Status	Disease	Primary Completion Date
2016-002671-10	P2	Completed	Psoriasis	2017-05-05
NCT03004846	P2	Completed	Psoriasis	2017-05-05
NCT02548052	P1	Completed	Psoriasis	2016-02-19

Recent News Events

Date	Type	Title
09/15/2023	News Article	Nuclear Receptor ROR-Gamma Market Research Report on Regional Size and Status 2023-2030
08/21/2023	PubMed	Inhibition of Nuclear Receptor Related Orphan Receptor γ Ameliorates Mechanical Hypersensitivity Through the Suppression of Spinal Microglial Activation.
04/08/2022	PubMed	Melatonin Nuclear Receptors Mediate Green-and-Blue-Monochromatic-Light-Combinations-Inhibited B Lymphocyte Apoptosis in the Bursa of Chickens via Reducing Oxidative Stress and Nfκb Expression.
02/05/2022	PubMed	Discovery of 2H-chromone-4-one based sulfonamide derivatives as potent retinoic acid receptor-related orphan receptor γt inverse agonists.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions